Methods and Results: Patients with ACS (Nϭ121) receiving IABP support were enrolled. Survivors and non survivors were compared at 30-days.
Background: Recent studies in large worldwide populations demonstrate that the metabolic syndrome (MS) increases the risk of acute myocardial infarction (AMI) without gender, ethnic or regional variations. The risk of AMI associated with MS appears no greater than the risk conferred by its individual components. Objective: The goal of the study is to investigate the prevalence of metabolic syndrome in young patients with acute myocardial infarction (AMI) treated with percutaneous coronary intervention (PCI) and to compare the ATP III individual components of MS in young versus old patients. Method: A retrospective analysis of the University of Southern California interventional cardiology database was performed to identify patients with AMI (STEMI and NSTEMI, nϭ779) treated with PCI between January 2008 and June 2011. Two groups were generated according to the patient's age: young (Յ45 years of age, nϭ81) and old (Ͼ45 years of age, nϭ698). Patients with MS were identified by the presence of at least 3 of the ATP III criteria and components of the MS were separately compared by age. Results: The MS was more prevalent in young patients with AMI (60.5% vs. 44.8%, pϭ0.02). Older patients were found to have higher rates of Hypertension (40.7% vs. 64.6%, pϽ0.001). Triglyceride levels were higher in younger patients (212mg/dl vs. 153.4mg/dl, p-valueϭ0.014), while HDL levels (38.18mg/dl vs. 40.18mg/dl, pϭ0.22) and obesity rates (BMI Ͻ 30kg/m2, 25.92% vs. 26.5%, pϭ0.97) were similar between the groups. Single vessel CAD was more common in younger with MS patients (44.6% vs. 71.7%, pϽ0.001), as well as total occlusion of the infarct related artery (39.7% vs. 19.1%, pϭ0.0003). Conclusions: The MS is highly prevalent in young patients with AMI. Younger patients compared to older patients with AMI treated with PCI have higher triglyceride levels, less hypertension, are more likely to have single vessel CAD and present with a totally occluded vessel.
CRT-13
Long in the context of MI yet many patients (pts), especially the uninsured do not receive DES. We evaluated BMS vs. DES in a public health system (PHS) population with uniform access to healthcare and stratified by presentation acuity. Methods: 2,000 pts undergoing PCI at a PHS hospital were analyzed as an open cohort. Pts were included if complete data were available and uniform access to healthcare was provided at the same PHS. Pts were analyzed by DES vs. BMS, stratified by stable vs. unstable (ACS, MI, shock) clinical presentation and followed for MACE (death, MI, urgent TVR). Results: 1,702 pts (57.2 Ϯ 10.2 yrs, 31.8% female, 45.9% AA, 22.5% White) underwent PCI for STEMI (19.2%), NSTEMI (28.0%), unstable angina (24.7%) or stable angina (18.9%). The majority (1,402, 82.4%) received BMS. Clinical follow-up was obtained in 85.1% of pts (nϭ1702, mean 2.5y Ϯ 1.9 yrs). MACE at 3 years was highest in unstable/BMS pts and lowest in stable/DES pts (Fig. 1) . Notably the difference between DES and BMS in the unstable cohort was driven by mortality reduction.
Conclusions: DES confers a MACE and likely mortality advantage over BMS, especially in unstable pts. DES was utilized in the minority of pts in this cohort, likely reflecting a significant selection bias. Additional multivariate analyses are currently underway to evaluate the true magnitude and mechanisms of benefit.
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CRT-14 Abbreviated Duration Eptifibatide In St Elevation Myocardial Infarction -Outcomes And Predictors Of Complications
Farrukh Hussain, Seeger Shen, Kerrett Wallace, Ali Bagherli, Roger K Philipp, James W Tam, Davinder S Jassal St. Boniface General Hospital, Winnipeg, MB, Canada Background: Previous literature has demonstrated the safety of abbreviated GP IIbIIIa infusion in elective PCI. There is no data to date on the safety of abbreviated infusion of GPIIbIIIa inhibition in the setting of primary PCI for STEMI. Methods and Results: A retrospective cohort of STEMI patients undergoing primary PCI from June 2009 -June 2011 was analyzed. Detailed demographic, intervention and complication data was collected. A logistic regression model was utilized to identify univariate and multivariate predictors of a pre-specified primary combined endpoint of death/vascular complication/transfusion/stent thrombosis. 66 patients with a mean age of 61 Ϯ 13 years (27% female, 26% diabetic) were identified. Six patients had cardiogenic shock on admission (9%). Symptom onset to device time was 312Ϯ318 min and lab to device time was 19Ϯ10 min. There were 6 patients (9%) with a pre lab cardiac arrest. Mean LVEF was 53Ϯ12 % and peak CK was 1991Ϯ2130U. Successful PCI (TIMI 3 flow and residual stenosis Յ 20%) was achieved in 64 (97%). Thrombectomy was performed in 45 (68%) patients. Stents were deployed in 65 (98%) with 1.6Ϯ0.5 stents (mean length 31Ϯ19) mm delivered to a mean of 1.1Ϯ0.4 lesions. Mean duration of 
